William (Bill) Russell

William Russell, MD
January 7, 2026

Longtime pediatric endocrinology director Bill Russell to focus on research, patient care

He has been succeeded on an interim basis by Jill Simmons, MD, professor of Pediatrics and founding director of the Program for Pediatric Metabolic Bone Disorders at Monroe Carell Jr. Children’s Hospital at Vanderbilt.

By Bill Snyder
Bill Russell, MD, left, with patient and trial participant Spencer Mannahan and his father, Zach. (photo by Evan Dorian)
January 22, 2025

Milestone in VUMC-affiliated diabetes screening and research program underscores impact of clinical trials

Screening and clinical trials are further advancing research to develop therapies that delay or prevent the progression to clinical disease in people at risk of developing Type 1 diabetes.

By Evan Dorian
February 2, 2024

Study links small pancreas size to faster progression to stage 3 Type 1 diabetes

The study findings, published in the journal Diabetes Care, suggest that pancreas imaging can have a benefit in tracking disease development and recruitment for preventive and therapeutic trials.

By Jill Clendening
March 23, 2023

Study sheds light on drug’s impact on diabetes progression

A Vanderbilt study of a treatment to delay the development of Type 1 diabetes in individuals at high risk did not meet the study goals of delaying progression from normal glucose tolerance to abnormal glucose tolerance or clinical diagnosis, although the study drug, abatacept, impacted immune response and preserved insulin production during the one-year treatment period.

By Craig Boerner
William Russell, MD, second from right, is the principal investigator for a study that uses a plasmid-based therapy to try to selectively desensitize the immune system in people with Type 1 diabetes. Shown here are, from left, Lana Howard, RN, CCRP; Brenna Hammel, RN, CPN; study participant Adam Brooks; Russell; and Robin Perkins, RN. Not pictured: Faith Brendle, RN, CPN, CCRP.
September 1, 2022

Trial participant steps up to help advance diabetes research

Vanderbilt is one of 16 North American sites conducting the Tolerance Using Plasmid in People with Type 1 Diabetes (TOPPLE) study, a phase 1 investigation that tests the safety and dosing of a new plasmid therapy.

By Jill Clendening
June 9, 2019

Study drug delays type 1 diabetes in high risk children and adults

Drug delays onset of type 1 diabetes by two years

By Craig Boerner